news

  • 7 July 2017
    Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK

    Additional space will provide purpose-built research laboratories accommodating around 450 scientists at Immunocore

    Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, and MEPC Limited (MEPC), a leading property developer and asset manager, announced today that Immunocore will expand its operations at Milton Park in Oxfordshire initially by a further 53,000 square feet (sq ft). The new purpose-built research laboratory facilities will support Immunocore’s continued growth in the area.

    Immunocore was established in 1999 and has been based at Milton Park since 2000, and currently occupies 135,000 sq ft of laboratory and office space. The Company will lease a new 53,000 sq ft purpose-built premises in the Enterprise Zone at 95 Park Drive and will also take further leases on a total of 48,000 sq ft in existing buildings at 96 Jubilee Avenue and 92 Park Drive on Milton Park. This forms a key part of Immunocore’s continued expansion plan on Milton Park. Planning consent for the new building at 95 Park Drive was obtained through the fast-track Local Development Order, which enables MEPC to secure consent for a wide range of development at Milton Park in just 10 days.

    The Milton Park expansion reflects the growing demand for state-of-the-art, strategically located premises from established and emerging science and technology businesses in Oxfordshire, which benefits from access to talent from the University of Oxford and excellent transport links into London and other key regional hubs.